Atrandi Biosciences

Atrandi Biosciences, founded in 2018 and based in Leiden, Netherlands, is a platform technology company focused on revolutionizing single-cell analysis. The company's proprietary Semi-Permeable Capsules (SPCs) allow researchers to process tens of thousands of individual cells in a single bulk reaction vessel while maintaining single-cell resolution, overcoming key scalability and workflow limitations of droplet-based methods. This positions Atrandi to address the growing demand in academic, biopharma, and diagnostic research for scalable, flexible, and true multiomic single-cell tools. The company appears to be in an early commercial stage, offering instruments and consumables to enable novel applications in genomics and diagnostics.

Semi-Permeable Capsules (SPCs): hydrogel-based, microscale compartments that isolate individual cells while allowing free diffusion of reagents. Enables bulk processing of thousands to millions of single cells in a single tube with sequential reaction steps, facilitating scalable single-cell multiomics.

Atrandi competes in the high-growth single-cell analysis market, directly challenging the dominant droplet microfluidics paradigm led by 10x Genomics. Its key differentiation is the non-droplet, bulk-processable SPC, which it positions as enabling easier, more flexible, and truly multi-step multiomic workflows. Other competitors include BD, Mission Bio, and various nano-well plate-based approaches.